Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
April 11, 2023 08:30 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight...
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
March 15, 2023 08:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial...
Hematologic Malignancies Testing Market Size Worth USD 5.45 Billion by 2027 | Increasing Research and Development Activities and Increasing Prevalence of Cancer are Significant Factors Influencing Industry Growth, says Emergen Research
March 01, 2021 10:47 ET
|
Emergen Research
Vancouver, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) -- The global Hematologic Malignancies Testing Market is forecasted to be worth USD 5.45 Billion by 2027, according to a current analysis...
Hematologic Malignancies Testing Market Size Worth USD 5.45 Billion by 2027 | Increasing Research and Development Activities and Increasing Prevalence of Cancer are Significant Factors Influencing Industry Growth, says Emergen Research
March 01, 2021 10:47 ET
|
Emergen Research
Vancouver, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) -- The global Hematologic Malignancies Testing Market is forecasted to be worth USD 5.45 Billion by 2027, according to a current analysis...
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies
May 21, 2019 06:00 ET
|
Invivoscribe, Inc.
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Invivoscribe, Inc., a vertically integrated global company focused on Improving Lives with Precision Diagnostics®, today announces expansion of space and...
INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “INMB”
February 04, 2019 08:55 ET
|
INmune Bio, Inc.
LA JOLLA, CA, Feb. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s innate immune system...